Dr. Lalitha Parameswaran, MD, MPH

Dr. Parameswaran practices at NYU Langone - Tisch Hospital in New York, New York.

Dr. Parameswaran's NPI, 1326291758, was assigned on October 29, 2008. Dr. Parameswaran holds New York license 269642.

Dr. Parameswaran's primary practice is NYU Langone - Tisch Hospital, at 550 1st Ave, New York, NY 10016 in New York County. The practice phone is (212) 263-1481.

Dr. Parameswaran's primary practice is NYU Langone - Tisch Hospital in New York, New York. Dr. Parameswaran is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Parameswaran to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Parameswaran practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Parameswaran's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Parameswaran is licensed in New York.

CMS data shows 219 Medicare services from Dr. Parameswaran across 4 procedure codes in 2024, for 111 Medicare patients. Medicare paid $21,895 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 111 Medicare patients who saw Dr. Parameswaran in 2024. The largest group is 75 to 84, with 39 patients. 75% of them have arthritis, and 75% have high blood pressure. 47% are also on Medicaid. Their average risk score is 3.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Parameswaran's median patient age at 51, with 56% women.

In 2024, Dr. Parameswaran wrote 19 Medicare Part D claims. 84% of them were for generic drugs. They cover 2 drugs, with $9,231 in total drug cost. In 2021, CMS named 112 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Parameswaran for performance year 2024, reported as part of a group. Dr. Parameswaran accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Parameswaran as offering telehealth.

CMS Open Payments shows 1 general payment to Dr. Parameswaran from 1 drug or device company in 2024. Education make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $18. It also lists 1 research payment totaling $3,200 in 2025.